2015

07/12/2015

Appendix 3B – Exercise of Options

27/11/2015

Appendix 3B – Exercise of options

20/11/2015

Results of Meeting

20/11/2015

Proteomics AGM Presentation

18/11/2015

Proteomics International receives R&D Tax Incentive

06/11/2015

Appendix 3B – Issue of Shortfall Options

04/11/2015

Proteomics Targets Key Asian Markets

30/10/2015

Appendix 4C – September 2015 Quarterly Report

27/10/2015

Proteomics granted US Patent for Diagnostic Test

26/10/2015

Proteomics Technical Presentation

20/10/2015

Notice of Annual General Meeting/Proxy Form

19/10/2015

Proteomics International Wins WA Industry and Export Award

19/10/2015

Change of Directors’ Interest Notices

19/10/2015

Initial Director’s Interest Notice

16/10/2015

Proteomics International Laboratories Appoints New Director

16/10/2015

Change of Directors’ Interest Notices

14/10/2015

Completion of Entitlement Issue and Shortfall notice

01/10/2015

Corporate Governance Statement and Appendix 4G

30/09/2015

Appendix 3B – Release from escrow

30/09/2015

Annual Report to shareholders

21/09/2015

Entitlement Issue Prospectus Despatch

16/09/2015

Release from escrow

15/09/2015

Letter to Ineligible Shareholders – Entitlement Issue

15/09/2015

Letter to Eligible Shareholders – Entitlement Issue

14/09/2015

Non-renounceable Pro-rata Options Entitlement Issue

11/09/2015

Entitlement Issue Prospectus

11/09/2015

Appendix 3B – Entitlement Issue

11/09/2015

Letter to option holders – Entitlement Issue

02/09/2015

Investor Presentation – September 2015

31/08/2015

Preliminary Final Report

19/08/2015

Investor Presentation – August 2015

31/07/2015

Appendix 4C – June 2015 Quarterly Report

30/06/2015

Appendix 3B – Release from escrow

23/06/2015

Appendix 3B – Release from escrow

16/06/2015

Release from escrow

10/06/2015

Investor Presentation – June 2015

09/06/2015

Ground-breaking Predictive Test for Diabetic Kidney Disease

09/06/2015

Release from escrow

05/06/2015

Appendix 3B – Release from escrow

22/05/2015

Release from escrow

21/05/2015

Diagnostic Test Patent Accepted for Diabetic Kidney Disease

19/05/2015

PILL appoints Global Head of Business Development

12/05/2015

Appendix 3B – Release from escrow

Subscribe
  • This field is for validation purposes and should be left unchanged.